NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

NervGen Pharma Corp. (NGEN) Stock Analysis

NervGen Pharma Corp. (NGEN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

NGEN

$2.33

+$0.01 (+0.43%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NGEN with… →

NGEN Key Statistics

As of Sep 4, 2026
Trading
Open
$2.31
Previous Close
$2.32
Day's Range
2.28–2.40
52-Week Range
1.58–6.30
Volume
920.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.73
Valuation
Market Cap
$250.53M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.57
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$44.12M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
107.52M
1-Year Return
−8.63%
Dividend and dates
Earnings Date
November 23, 2026estimated
Avg Volume
687.20K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NGEN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−58.39%
2025+156.88%
2024+6.86%
2023+71.43%
2022−44.13%
2021+22.41%
2020+10.13%
2019 (partial year)+21.45%

As of September 4, 2026.

NGEN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$44.12M—
2024$0.00−$24.25M—
2023$0.00−$22.38M—
2022$0.00−$20.72M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$25.08M−$44.12M—
2024$0.00—−$25.18M−$24.25M—
2023$0.00—−$17.78M−$22.38M—
2022$0.00—−$23.03M−$20.72M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NGEN Valuation vs Biotechnology Median

Median of 656 stocks
MetricNGENBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values NervGen Pharma Corp. (NGEN) at $250.53M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 9.

Over the past 52 weeks the price has ranged from $1.58 to $6.30. The most recent close on file for NGEN is $2.33, dated September 4, 2026. That is +$0.01 (+0.43%) against the previous close. The latest close sits 47.47% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $44.12M. The reported profit margin is 0%. Trailing earnings per share are −0.57.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 0.73. Daily returns over the trailing 7 years annualize to a volatility of 76.77%. Over the trailing twelve months the price has returned −8.63%. Across 5 years the annualized return works out at +7.42%.

Growth & Income

No dividend is on file for NGEN.

The strongest complete calendar year on file is 2025 at +156.88%; the weakest is 2022 at −44.13%. Of the 6 complete calendar years on file, 5 finished higher. 2026 is still running; the price is −58.39% year to date.

Peer Comparison

NervGen Pharma Corp. (NGEN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
NervGen Pharma Corp. NGEN $250.53M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. NervGen Pharma Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About NervGen Pharma Corp.

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Visit website →